
    
      This is a single-arm, open-label, Phase 2 study to assess the anti-tumor efficacy of oral
      single agent HM61713 administered to patients with T790M-positive NSCLC after treatment with
      an EGFR-TKI as measured by objective response rate (ORR).
    
  